公开(公告)号：US20240059799A1

公开(公告)日：2024-02-22

申请号：US18314339

申请日：2023-05-09

Applicant: Pfizer Inc. ,  Bristol-Myers Squibb Company

Inventor： James Reasoner APGAR ,  Laird BLOOM ,  Fang JIN ,  Fridrik KARLSSON ,  Kimberly Ann MARQUETTE ,  Jessica Haewon MIN DEBARTOLO ,  Nicole Melissa PICHE-NICHOLAS ,  Lioudmila TCHISTIAKOVA

IPC: C07K16/46 ,  A61P37/02 ,  C12N15/63

CPC classification number: C07K16/468 ,  A61P37/02 ,  C12N15/63 ,  C07K2317/14 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.

公开(公告)号：US20240117030A1

公开(公告)日：2024-04-11

申请号：US18175796

申请日：2023-02-28

Applicant: Pfizer Inc.

Inventor： Rita Diane AGOSTINELLI ,  James Reasoner APGAR ,  Eric Matthew BENNETT ,  Laird BLOOM ,  Ting CHEN ,  Aaron Michael D'ANTONA ,  Arnab DE ,  Fang JIN ,  Marion Teresa KASAIAN ,  Matthew Allister LAMBERT ,  Kimberly Ann MARQUETTE ,  Virginie MCMANUS ,  Jessica Haewon MIN DEBARTOLO ,  Nicole Melissa PICHE-NICHOLAS ,  Richard Thomas SHELDON ,  Lioudmila TCHISTIAKOVA ,  Alexander Michael Shuford BARRON ,  Richard Lee GIESECK, III ,  Xiaotian ZHONG

IPC: C07K16/24 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/247 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

公开(公告)号：US20240376225A1

公开(公告)日：2024-11-14

申请号：US18576896

申请日：2022-07-06

Applicant: Hulian GAO ,  The Children's Medical Center Corporation ,  PFIZER INC.

Inventor： Hulian GAO ,  Michael C. CARROLL ,  Oleg Victorovich KOVALENKO ,  Eric Matthew BENNETT ,  Janet Elizabeth BUHLMANN ,  Xianchun TANG ,  Stefano Vincenzo GULLA ,  Nathan HIGGINSON-SCOTT ,  Fridrik Jensen KARLSSON ,  Dulce SOLER-FERRAN ,  Jessica Haewon MIN DEBARTOLO

IPC: C07K16/28 ,  A61P37/06

Abstract: Provided herein are anti-CD21 antibodies or antigen binding fragments thereof and their use in the treatment of autoimmune diseases or disorders.